



The first total synthesis and structural determination of benzopyrenomycin

Seijiro Hosokawa *, Yuki Mukaeda, Ryo Kawahara, Kuniaki Tatsuta *

Department of Applied Chemistry, Faculty of Science and Engineering, Waseda University, 3-4-1 Ohkubo, Shinjuku-ku, Tokyo 169-8555, Japan

ARTICLE INFO

Article history:

Received 30 July 2009

Revised 12 September 2009

Accepted 17 September 2009

Available online 23 September 2009

ABSTRACT


The first total synthesis and structural determination of benzopyrenomycin has been achieved. This synthesis contains remarkable transformations including cyclization to afford the benzanthrone skeleton, *syn*-selective vinylogous Mukaiyama aldol reaction, and radical cyclization with the benzanthrone attaching the iodoalkane chain.

© 2009 Elsevier Ltd. All rights reserved.

Benzopyrenomycin (**1**) was isolated as an antitumor from a culture broth of *Streptomyces lavendulae* (strain Tü 1668).¹ This compound is the first known natural product with a benzo[*a*]pyrene framework (Fig. 1). The structure of benzopyrenomycin (**1**) was determined by NMR spectra. Although the relative structure of **1** was determined, insufficient amount of the isolated **1** made it unsuccessful to determine the absolute configuration. Isolation of rubiginone A₂,² having a similar optical rotation with **1**, from the same culture broth gave presumption of the absolute stereochemistry of benzopyrenomycin as shown in Figure 1.¹ Interested in the structure and bioactivities, we embarked the synthesis of **1** to determine the absolute configuration.

Recently, we have developed stereoselective vinylogous Mukaiyama aldol reactions using the chiral silyl ketene *N,O*-acetals to give γ,δ -*anti*- α,β -unsaturated imides.³ For example, the reaction using vinylketene silyl *N,O*-acetal **2** with 4-bromobenzaldehyde (**3**) gave *anti*-**4** predominantly (Scheme 1).^{3g} The feature of the ¹H NMR spectrum of *anti*-**4** in CDCl₃ was the signal of H5, which existed at δ 4.28 ppm with a large coupling constant ($J_{4,5} = 9.0$ Hz), while H5 of *syn*-**4** was present at δ 4.85 ppm with a small coupling constant ($J_{4,5} = 3.0$ Hz). During the further studies of the reaction, we found that 1-formylpyrene (**5**) reacted with vinylketene silyl *N,O*-acetal **2** to give *syn*-adduct (*syn*-**6**) predominantly, of which H5 was found at δ 6.07 ppm with the small coupling constant ($J_{4,5} = 3.5$ Hz).⁴ Investigation of the origin of the *syn*-selectivity has been in progress;⁵ however, we have decided to apply this phenomenon to the total synthesis of natural products.

Our synthetic plan of benzopyrenomycin (**1**) is shown in Scheme 2. Because of the remarkable conjugation system of benzopyrenomycin (**1**), C1–C12a bond could be constructed with iodide **7** in the final stage of the synthesis. The stereogenic




Benzopyrenomycin (**1**)

Figure 1. Structure of benzopyrenomycin (**1**).


centers, C2 and C3, would be constructed by our *syn*-selective asymmetric induction method using the chiral dienol ether *ent*-**2**. Tetracyclic aldehyde **8** might be synthesized by the introduction of acetate unit to anthraquinone **9** at C12 position followed by cyclization.

Total synthesis was started by Diels–Alder reaction with quinone **10**⁶ and diene **11**⁷ (Scheme 3). Treatment of the labile adduct **12** with DBU under air promoted successive reactions including the elimination of AcOH, aromatization of the right ring, and air-oxidation to give anthraquinone **9**. The regioselectivity of the Diels–Alder reaction was confirmed by NOE and HMBC of anthraquinone **9** (Fig. 2). Correlation between H5 and C6 supported the structure of **9**, the desired product. Reduction of **9** with LiAlH₄ followed by IBX oxidation provided the unstable aldehyde **13**. The acetate unit for C11–C14 of benzopyrenomycin (**1**) was introduced at once by Wittig reaction to afford the stable α,β -unsaturated ester **14**. Benzannulation⁸ to afford benzanthrone **15** was achieved by absorption of γ proton of the α,β -unsaturated ester **14** with sodium methoxide. Condensation at α position of the ester formed C10b–C11 bond smoothly to give benzanthrone **15** in high yield. The structure of **15** was confirmed by HMBC and NOE as shown in Figure 3. Correlation between H12 and C10b made it clear that the product of this reaction possessed the tet-

* Corresponding authors. Tel./fax: +08 3 3200 3203 (K.T.).
E-mail address: tatsuta@waseda.jp (K. Tatsuta).




Scheme 1. Vinylogous Mukaiyama aldol reactions using 4-bromobenzaldehyde **3** and 1-formylpyrene **5**.



Scheme 2. Retrosynthetic analysis of benzopyrenomycin (**1**).

racyclic structure. Tetracyclic **15** was converted to aldehyde **8** by one-pot transformation including bromination of the C3 position and subsequent DMSO oxidation.



Scheme 3. Reagents and conditions: (a) PhMe, 110 °C, 74%; (b) DBU, PhMe, rt, 76%; (c) LiAlH₄, THF–CH₂Cl₂, 0 °C, 5 min; IBX, PhMe–DMSO, 50 °C, 1 h, 54%; (d) Ph₃P=CHCO₂Me, PhMe, 80 °C, 5 h, 83%; (e) NaOMe, MeOH, rt, 12 h, 95%; (f) NBS, AIBN, CCl₄, 80 °C, 1 h, then DMSO, 80 °C, 1 day, 91%.

Achievement of the total synthesis of benzopyrenomycin (**1**) is shown in **Scheme 4**. Treatment of aldehyde **8** with the chiral dienol ether **ent-2** in the presence of BF₃·OEt₂ at –60 °C gave alcohol **16** having the desired stereogenic centers. The coupling constant between H2 and H3 ($J = 3.4$ Hz) revealed *syn*-relation as expected. The absolute configuration of **16** was determined by Mosher's method.⁹ The hydroxy group of **16** was protected as TBS ether **17**. The double bond cleavage of the α,β -unsaturated imide **17** by ozonolysis was followed by reduction to afford alcohol **18**. The primary alcohol **18** was converted to iodide **7**, which was submitted to the radical cyclization to produce C1–C12a bond. Treatment of **7** with tributyltin hydride (4 equiv) in the presence of dibenzoyl peroxide (3 equiv) in toluene at 80 °C promoted cyclization¹⁰ and sequential oxidation to provide benzo[*a*]pyrene **19**. The structure of **19** was confirmed by correlation between H1 and C12 as well as NOE between H2 and the methyl group of TBS (Fig. 4). De-O-protection with HF-pyridine proceeded smoothly to give benzopyrenomycin (**1**) as yellow needles. The spectral data of synthetic **1** including ¹H and ¹³C NMR, IR, and HR-MS were identical with those of natural product as well as the dextro-rotation of the yellow solution [synthetic **1**: $[\alpha]_D^{24} +25$ (c 0.3, CHCl₃); lit.¹ (natural **1** [a yellow solid]) $[\alpha]_D^{20} +38$ (c 0.3, CHCl₃)].¹¹ Therefore, the absolute




Figure 2. Structure of anthraquinone **9**.




Figure 4. Structure of benzo[a]pyrene **19**.




Figure 3. Structure of benzanthrone **15**.

structure of benzopyrenomycin (**1**) was determined to be (2*R*,3*S*)-configuration.

In conclusion, the first total synthesis and structural determination of benzopyrenomycin has been achieved. This synthesis contains remarkable transformations including cyclization to afford benzanthrone skeleton (**14**→**15**), *syn*-selective vinylogous Mukaiyama aldol reaction (**8**→**16**), and radical cyclization with the benzanthrone attaching the iodoalkane chain (**7**→**19**). The absolute structure of benzopyrenomycin (**1**) was determined as (2*R*,3*S*)-configuration.

Acknowledgments

This work was financially supported by the Consolidated Research Institute for Advanced Science and Medical Care, the Global COE program 'Center for Practical Chemical Wisdom', and Scientific Research on Priority Area 'Creation of Biologically Functional Mol-


ecules' from the Ministry of Education, Culture, Sports, Science and Technology.

Supplementary data

The spectral data of compounds **7**, **8**, **9**, **15**, **16**, **19**, and synthetic benzopyrenomycin (**1**), ¹H NMR spectrum (600 MHz in CDCl₃ and 600 MHz in DMSO-*d*₆), and ¹³C NMR (150 MHz in CDCl₃ and 150 MHz in DMSO-*d*₆) spectrum of synthetic benzopyrenomycin (**1**) are available. Supplementary data associated with this article can be found in the online version at doi:10.1016/j.tetlet.2009.09.089.


References and notes

- Huang, X.; He, J.; Niu, X.; Menzel, K.-D.; Dahse, H.-M.; Grabley, S.; Fielner, H. P.; Sattler, I.; Hertweck, C. *Angew. Chem., Int. Ed.* **2008**, *47*, 3995–3998.
- Oka, M.; Kamei, H.; Hamagishi, Y.; Tomita, K.; Miyaki, T.; Konishi, M.; Oki, T. *J. Antibiot.* **1990**, *43*, 967–976.
- (a) Hosokawa, S.; Tatsuta, K. *Mini-Rev. Org. Chem.* **2008**, *5*, 1–18; (b) Hosokawa, S.; Yokota, K.; Imamura, K.; Suzuki, Y.; Kawarasaki, M.; Tatsuta, K. *Chem. Asian J.* **2008**, *3*, 1415–1421; (c) Shirokawa, S.; Shinoyama, M.; Ooi, I.; Hosokawa, S.; Nakazaki, A.; Kobayashi, S. *Org. Lett.* **2007**, *9*, 849–852; (d) Hosokawa, S.; Kuroda, S.; Imamura, K.; Tatsuta, K. *Tetrahedron Lett.* **2006**, *47*, 6183–6186; (e) Hosokawa, S.; Yokota, K.; Imamura, K.; Suzuki, Y.; Kawarasaki, M.; Tatsuta, K. *Tetrahedron Lett.* **2006**, *47*, 5415–5418; (f) Tatsuta, K.; Hosokawa, S. *Chem. Rev.* **2005**, *105*, 4707–4729; (g) Hosokawa, S.; Ogura, T.; Togashi, H.; Tatsuta, K. *Tetrahedron Lett.* **2005**, *46*, 333–337; (h) Shirokawa, S.; Kamiyama, M.; Nakamura, T.; Okada, M.; Nakazaki, A.; Hosokawa, S.; Kobayashi, S. *J. Am. Chem. Soc.* **2004**, *126*, 13604–13605.



Scheme 4. Reagents and conditions: (a) BF₃·OEt₂, CH₂Cl₂, –60 °C, 86%; (b) TBSOTf, 2,6-lutidine, CH₂Cl₂, 0 °C, 5 min, 91%; (c) O₃, CH₂Cl₂–MeOH, –78 °C, then Me₂S; LiAlH(Ot-Bu)₃, THF, 0 °C, 87%; (d) I₂, PPh₃, imidazole, PhMe, 50 °C, 88%; (e) *n*-Bu₃SnH, benzoyl peroxide, PhMe, 80 °C, 5 h, 85%; (f) HF–pyridine, MeCN, rt, 5 min, 76%.

4. The absolute configuration of **syn-6** was determined by Mosher's method⁹ and derivation to the cyclic compound **20** as shown below.



- Recently, Kobayashi's group revealed that reactions of *N,O*-acetal **2** with α -heteroatom-substituted aldehydes gave *syn*-adduct predominantly: Shinonyama, M.; Shirokawa, S.; Nakazaki, A.; Kobayashi, S. *Org. Lett.* **2009**, *11*, 1277–1280.
- (a) Hosokawa, S.; Fumiyaama, H.; Fukuda, H.; Fukuda, T.; Seki, M.; Tatsuta, K. *Tetrahedron Lett.* **2007**, *48*, 7305–7308; (b) Hosokawa, S.; Fumiyaama, H.; Fukuda, H.; Fukuda, T.; Seki, M.; Tatsuta, K. *Heterocycles* **2008**, *76*, 699–713.
- (a) Shing, T. K. M.; Tang, Y.; Malone, J. F. *J. Chem. Soc., Chem. Commun.* **1989**, 1294–1295; (b) Shing, T. K. M.; Tang, Y. *Tetrahedron* **1990**, *46*, 2187–2194.
- For the recent review of benzannulation: Kotha, S.; Misra, S.; Halder, S. *Tetrahedron* **2008**, *64*, 10775–10790.
- Ohtani, I.; Kusumi, T.; Kashman, Y.; Kakisawa, H. *J. Am. Chem. Soc.* **1991**, *113*, 4092–4096.
- For the radical cyclization with the benzene derivative attaching the iodoalkane chain: Ollivier, C.; Bark, T.; Renaud, P. *Synthesis* **2005**, 1459–1466.
- Benzopyrenomycin (**1**) received air-oxidation easily in $CDCl_3$ at room temperature, while air-oxidation of **1** in $DMSO-d_6$ proceeded very slowly.